Lefter to the Editor

The combination of hydralazine and isosorbide dinitrate: the only antioxidant treatment recommended in the guidelines

Dear Editor,

We read the article 'Cardiovascular diseases: oxidative damage and antioxidant protection' by Zhang et al with great interest¹. In this article, it was focused on the well-known antioxidant vitamins of ascorbic acid (vitamin C), beta-carotene (vitamin A) and alpha-tocopherol (vitamin E). However there is no clinical trial demonstrating preventing effects of supplemental vitamins from the cardiovascular diseases. Only 200 mg/day of vegetables, 200 mg/day of fruits and 35-40 mg/day of fiber containing food are recommended in the guidelines². As a matter of fact bilberry, high bush blueberry, blackberry, strawberry, raspberry, kale, spinach, Brussels sprout, alfalfa and broccoli show higher total antioxidant capacity (TAC) than the fruits and vegetables including well-known antioxidant vitamins such as grapefruit, melon, kiwi onion, lettuce or red pepper³. This paradoxical situation is associated with the non-vitamin antioxidants of polyphenols and anthocyanins. The studies demonstrated that the contribution of polyphenols and anthocyanins to TAC was much higher than those of the Vitamin A, C and E³.

The solely antioxidant therapy which is recommended in guidelines is the combination of hydralazine and isosorbide dinitrate (Hyd-ISDN)⁴. In the V-Heft and A-Heft trials, it has been shown that Hyd-ISDN combination reduced mortality rates in patients with heart failure⁴⁻⁶. It was revealed that hydralazine and nitrates reduced superoxide production by inhibiting NADPH-Oxidase, thereby improved nitroso-redox balance both in the endothelial cells and also in the cardiomyocytes⁷⁻⁹. Furthermore hydralazine precludes nitrate tolerance emerging in long lasting nitrate therapies⁸. We demonstrated that Hyd-ISDN decreased oxidative stress and reduced sarcoplasmic reticulum calcium leak and restored calcium content in an experimental model of nitroso-redox imbalance⁹. Thereby, Hyd-ISDN normalized impaired sarcomere length shortening. It seems that this combination leads to positive effects through decreasing oxidative stress.

Therefore, in a review addressing oxidative stress in cardiovascular diseases, we believe that discussing also Hyd-ISDN might be useful for researchers dealing with oxidative stress.

Conflict of Interest

The Authors declare that there are no conflicts of interest.

References

- 1) ZHANG PY, Xu X, Li XC. Cardiovascular diseases: oxidative damage and antioxidant protection. Eur Rev Med Pharmacol Sci 2014; 18: 3091-3096.
- 2) PERK J, DE BACKER G, GOHLKE H, GRAHAM I, REINER Z, VERSCHUREN M, ALBUS C, BENLIAN P, BOYSEN G, CIFKOVA R, DEATON C, EBRAHIM S, FISHER M, GERMANO G, HOBBS R, HOES A, KARADENIZ S, MEZZANI A, PRESCOTT E, RYDEN L, SCHERER M, SYVÄNNE M, SCHOLTE OP REIMER WJ, VRINTS C, WOOD D, ZAMORANO JL, ZANNAD F; EUROPEAN ASSOCIATION FOR CARDIOVASCULAR PREVENTION & REHABILITATION (EACPR); ESC COMMITTEE FOR PRACTICE GUIDELINES (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33: 1635-1701.
- 3) HARASYM J, ÖLEDZKI R. Effect of fruit and vegetable antioxidants on total antioxidant capacity of blood plasma. Nutrition 2014; 30: 511-517.

- 4) YANCY CW, JESSUP M, BOZKURT B, BUTLER J, CASEY DE JR, DRAZNER MH, FONAROW GC, GERACI SA, HORWICH T, JANUZZI JL, JOHNSON MR, KASPER EK, LEVY WC, MASOUDI FA, MCBRIDE PE, MCMURRAY JJ, MITCHELL JE, PETERSON PN, RIEGEL B, SAM F, STEVENSON LW, TANG WH, TSAI EJ, WILKOFF BL; AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION/AMERICAN HEART ASSOCIATION TASK FORCE ON PRACTICE GUIDELINES. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 240-327.
- COHN JN, ARCHIBALD MP, ZIESCHE S, FRANCIOSA JA, HARSTON WE, TRISTANI FE, DUNKMAN WB, JACOBS W, FRANCIS GS, FLOHR KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547-1552.
- 6) Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN; African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart Failure. N Engl J Med 2004; 351: 2049-2057.
- 7) ECHOLS MR, YANCY CW. Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure. Vasc Health Risk Manag. 2006; 2: 423-431.
- 8) MÜNZEL T, STEVEN S, DAIBER A. Organic nitrates: Update on mechanisms underlying vasodilation, tolerance and endothelial dysfunction. Vascul Pharmacol. 2014; 63: 105-113.
- 9) DULCE RA, YIGINER O, GONZALEZ DR, GOSS G, FENG N, ZHENG M, HARE JM. Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance. J Biol Chem 2013; 288: 6522-6533.

O. Yiginer¹, A. Tokatli², A. Haholu³, N. Ozmen¹

¹Department of Cardiology, GATA Haydarpasa Hospital, Istanbul, Turkey ²Department of Cardiology, Golcuk Military Hospital, Kocaeli, Turkey ³Department of Pathology, GATA Haydarpasa Hospital, Istanbul, Turkey